SCHEMBL4158059

SCHEMBL4158059

CN(C(=O)NN1CCOCC1)c1ccc(SC(F)(F)F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.37
CYP2D6 P10635 1/20 0.36
FKBP1A P62942 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 2/20 0.33
ALOX5 P09917 1/20 0.33
KCNK3 O14649 1/20 0.33
MEN1 O00255 1/20 0.33
MLYCD O95822 1/20 0.33
PDK2 Q15119 1/20 0.33
ALDH1A1 P00352 2/20 0.33
RAB9A P51151 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150565 0.83 CASR (0.43) CASRLMNAALDH1A1
SCHEMBL13774592 0.81 CYP2D6 (0.39) CYP2D6KMT2ASMN1; SMN2LMNAMEN1
SCHEMBL4145149 0.80 TACR2 (0.36) MMP1MMP2MMP3MMP9MMP8
SCHEMBL4149723 0.79 TSHR (0.38) LMNAPDK2ALDH1A1
SCHEMBL4142460 0.78 LMNA (0.35) LMNAPDK2ALDH1A1
SCHEMBL4163032 0.76 PDK2 (0.33) CASRKCNK3PDK2
SCHEMBL4154041 0.76 EPHX2 (0.39) LMNAPDK2
SCHEMBL4142022 0.76 PTPRZ1 (0.37) SMN1; SMN2LMNAPDK2ALDH1A1
SCHEMBL4158539 0.76 MAPT (0.36) LMNAALDH1A1
SCHEMBL4154203 0.75 MAPK1 (0.34) CASRFKBP1AMLYCDALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
EP-1937629-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-07-02 EP disclosed
WO-2007046513-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-26 WO disclosed
WO-2007046513-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176786-A1 Benzoylurea Compounds and Use Thereof BTK, BRIX1, NFXL1 CASR 1722/4885CYP2D6 2482/4885FKBP1A 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.